CAG
MGRX icon

Csenge Advisory Group’s Mangoceuticals MGRX Stock Holding History

Csenge Advisory Group’s Portfolio MGRX Stock Details MGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.8K Hold
10,000
– – ﹤0.01% 763
2026
Q1 		$3.6K Hold
10,000
– – ﹤0.01% 746
2025
Q4 		$7.4K Buy
+10,000
New +$16.2K ﹤0.01% 711

Other funds holding MGRX

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
ACA
Ackerman Capital Advisors Dallas, Texas $497M AUM 16.31% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Csenge Advisory Group's MGRX Position: Q2 2026 in Review

Csenge Advisory Group held its Mangoceuticals (MGRX) position steady in Q2 2026 at 10,000 shares worth $3.8K. The position accounts for ﹤0.01% of the portfolio, ranked #763.

Csenge Advisory Group first reported a position in MGRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $7.4K in Q4 2025. 18 funds tracked by Wall St. Rank hold MGRX as of Q2 2026.

  • Csenge Advisory Group held 10,000 shares of Mangoceuticals worth $3.8K as of Q2 2026.
  • Csenge Advisory Group left its Mangoceuticals share count unchanged in Q2 2026.
  • Mangoceuticals made up ﹤0.01% of Csenge Advisory Group's portfolio in Q2 2026, its #763 holding.
  • Csenge Advisory Group first reported a position in Mangoceuticals in Q4 2025 and has held it in 3 quarters since.
  • Csenge Advisory Group's Mangoceuticals position peaked at $7.4K in Q4 2025.
  • 18 funds tracked by Wall St. Rank held Mangoceuticals as of Q2 2026.

Based on Csenge Advisory Group's 13F filing for Q2 2026, filed 10 Aug 2026.